Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is... see more

Recent & Breaking News (CSE:RVV)

Some of the World's Top Companies May be Nearing a Pandemic Treatment

Livemoney August 20, 2020

IIROC Trade Resumption - RVV

Canada NewsWire August 19, 2020

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

GlobeNewswire August 19, 2020

IIROC Trading Halt - RVV

Canada NewsWire August 19, 2020

60 Minutes: Psychedelics Could Help People with Addiction and Anxiety

Livemoney August 18, 2020

These Are Some of The Top Companies Racing to Develop a Pandemic Treatment

Livemoney August 14, 2020

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire August 14, 2020

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

GlobeNewswire August 11, 2020

This Landmark Decision is a Major Game Changer for Companies Focused on Psylocybin

Livemoney August 10, 2020

Landmark Decision Allows Patients to Possess and Use Psilocybin

Livemoney August 6, 2020

These are Some of the Top Companies Nearing a Potential Pandemic Treatment

Livemoney August 5, 2020

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire August 5, 2020

Data Raising Hopes for a Pandemic Treatment in 2020

Livemoney August 3, 2020

These are Some of the Top Companies Racing to Produce Pandemic Treatments

Livemoney July 31, 2020

UPDATE - Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire July 31, 2020

IIROC Trade Resumption - RVV

Canada NewsWire July 31, 2020

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire July 31, 2020

IIROC Trading Halt - RVV

Canada NewsWire July 31, 2020

IIROC Trade Resumption - RVV

Canada NewsWire June 30, 2020

Revive Therapeutics Announces Submission of Investigational New Drug Application (IND) with U.S. FDA for Phase 3 Confirmatory Study for Bucillamine in COVID-19

GlobeNewswire June 30, 2020